Dear Editor,

Philadelphia chromosome-positive (Ph+) or *BCR-ABL1*-positive AML accounts for \<1% of newly diagnosed AML cases \[[@B1]\]. Although the role of Ph in CML pathogenesis has been elucidated, Ph+ AML pathogenesis remains controversial. Ph+ AML is believed to represent the *de novo* myeloid blast phase (BP) of CML and, therefore, was not recognized in the 2008 WHO classification of myeloid neoplasms and acute leukemia \[[@B2]\].

Konoplev et al. \[[@B3]\] presented molecular evidence suggesting that Ph+ AML is a clinicopathological entity distinct from CML-BP, in a study involving nine patients with Ph+ AML and five patients with CML-BP at their initial presentations. They showed that patients with Ph+ AML carried the nucleophosmin (*NPM1*) mutation at a similar frequency as that seen in all cases of AML, and that they lacked *ABL1* mutations that occur in a proportion of patients with CML-BP. Internal tandem duplication (ITD) of the Fms-like receptor tyrosine kinase 3 (*FLT3*) was detected in a Ph+ AML patient, but no Ph+ AML patients harbored both the *NPM1* mutation and the *FLT3* ITD. We present a rare case of *BCR-ABL1*-positive AML with both the *NPM1* mutation and the *FLT3* ITD.

A 79-yr-old woman was referred to our hospital after several months of general weakness and weight loss. She had undergone surgery for acute appendicitis one year earlier. Her initial white blood cell count was 157.5×10^9^/L (80% blasts and 1% basophils), hemoglobin was 11.8 g/dL, and platelet count was 87×10^9^/L. She did not show organomegaly or lymphadenopathy. Her bone marrow (BM) was packed with blasts (92.3% of all nucleated cells) with cup-like nuclear indentation ([Fig. 1](#F1){ref-type="fig"}) and showed no significant dyshematopoietic features. Flow cytometry revealed that the blasts were positive for CD13 (94%), CD33 (98%), CD34 (72%), HLA-DR (46%), and cytoplasmic myeloperoxidase (86%). Chromosome analysis revealed t(2;5)(p12;p15) in 20 metaphases, which was considered a constitutional chromosomal abnormality. Multiplex reverse transcription (RT)-PCR using HemaVision kit (DNA Diagnostic A/S, Risskov, Denmark) revealed the presence of minor *BCR-ABL1* (e1a2) fusion transcripts. Interphase FISH analysis of formalin-fixed paraffin-embedded tissue from BM trephine biopsy section showed no fusion signals by using locus specific identifier BCR/ABLdual-color, dual-fusion translocation probe set (Abbott Molecular/Vysis, Des Plaines, IL, USA).

Genomic DNA was amplified to detect the *FLT3* ITD and *NPM1* exon 12 mutations. Total RNA was extracted and RT-PCR was carried out to amplify the BCR/ABL kinase domain. Direct sequencing of the amplified products revealed that our patient had type A mutations of *NPM1* ([Fig. 2A](#F2){ref-type="fig"}) and *FLT3* ITD ([Fig. 2B](#F2){ref-type="fig"}), but no *ABL1* mutations.

The patient was diagnosed as having AML without maturation, according to the 2008 WHO classification of haematopoietic and lymphoid tumors \[[@B4]\], and was considered to have a cryptic e1a2 *BCR-ABL1* fusion. Although cytarabine and decitabine therapy was started, the patient died one week after AML diagnosis.

The clinicopathological features that suggested Ph+ AML rather than CML-BP included the absence of a clinical history of hematologic disorders (including CML and MDS); no dwarf megakaryocytes, splenomegaly, or basophilia; and the absence of an extra Ph, trisomy 8, trisomy 19, or isochromosome 17q \[[@B3][@B5]\]. This case showed clinical and laboratory features compatible with Ph+ AML, as mentioned above.

Considering the findings of Konoplev\'s cases \[[@B3]\] and this case, *NPM1* mutations and *FLT3* ITD may be concurrent genetic abnormalities in patients with Ph+ AML. The coexistence of the *FLT3* ITD and the *NPM1* mutations, as observed in our patient, is reported in about 40% of patients with AML and mutated *NPM1* \[[@B6]\]. This case supports the idea that Ph+ AML is a distinct entity. Another study also showed that *NPM1* mutations occur only in patients with AML and not in those with CML, whereas *ABL1* mutations are common in patients with CML \[[@B7]\]. Furthermore, a high-resolution array-based comparative genomic hybridization study indicated that a unique loss within immunoglobulin genes provides a simple test to differentiate clinically similar *de novo* Ph+ AML cases from CML-BP cases \[[@B1]\].

To our knowledge, our patient is the first case of Ph+ AML with both *FLT3* ITD and *NPM1* mutations. Ph+ AML cases seem to have different molecular or genomic features from those with CML-BP \[[@B1][@B3][@B8]\]. However, to describe Ph+ AML as a discrete entity in the WHO classification, it is important to document more cases and perform more aggressive diagnostic workups, including *FLT3* ITD and *NPM1* mutational analyses and analysis of immunoglobulin genes. Especially, a hematopathologist should keep in mind that cup-like nuclei and fish mouth nuclei may represent an important morphologic clue to provoke testing for both the *FLT3* ITD and the *NPM1* mutations \[[@B9][@B10]\].
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![Bone marrow findings of the patient. (A) Aspirate smear showing increased blasts (Wright-Giemsa, ×1,000). The blasts with cup-like nuclei and fish mouth nuclei (inlet) are observed. (B) Biopsy section showing a diffuse infiltration by the blasts (Hematoxylin and eosin, ×200).](alm-36-263-g001){#F1}

![Sequencing analyses show the presence of type A mutation (c.863_864insTCTG) in the nucleophosmin gene (*NPM1*) (A) and an *FLT3* internal tandem duplication (ITD) with a 45 bp in-frame duplication (c.1788_1832dup) (B). Arrows indicate the insertion sites.](alm-36-263-g002){#F2}
